PZ703b TFA
Based on 4 publication(s) in Google Scholar
PZ703b TFA is a Bcl-xl PROTAC degradation agent that induces apoptosis and inhibits cancer cell proliferation for bladder cancer research.
(Pink: Bcl-xL ligand (HY-184547); Blue: VHL ligand (HY-112078); Black: linker (HY-W014787)).
For research use only. We do not sell to patients.
- Purity: 98.89%
- Formula: C82H103ClF6N10O13S4
- Molecular Weight:1714.46
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) PZ703b TFA
MoreAll PROTACs Isoforms
More
Biological Activity
|
Bcl-xL |
PZ703b (0-1 μM, 24 h) TFA can synergistically inhibit bladder cancer cell proliferation with Mivebresib in a dose-dependent manner and induce apoptosis in bladder cancer cells via the mitochondrial pathway[1].
PZ703b (0-1 μM, 48 h) TFA inhibits MOLT-4 and RS4;11 cells with the IC50 values of 15.9 and 11.3 nM respectively[2].
PZ703b (10 nM, 48 h)TFA induces rapid and durable BCL-XL degradation and apoptosis in MOLT-4 cells through the caspase-3 mediated pathway[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Bladder cancer cell lines 5637, SW780, and HT-1977
-
Concentration:1 μM
-
Incubation Time:24 hours
-
Result:Induction of Bcl-xl degradation increased the association between Mcl-1 and Bim (a pro-apoptotic Bcl-2 protein). It was further shown that forced expression of Bcl-xl or Mcl-1 significantly reduced PZ703b-induced apoptosis.
Resulted in a slight activation of Bax and Bak.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1714.46
-
Formula C82H103ClF6N10O13S4
-
Color White to off-white
-
SMILES
ClC1=CC=C(C=C1)C2=C(C[C@](CNC(CCCCCCCCC(N[C@H](C(N3C[C@@H](C[C@H]3C(N[C@@H](C)C4=CC=C(C=C4)C5=C(N=CS5)C)=O)O)=O)C(C)(C)C)=O)=O)(CC2)C)CN6CCN(CC6)C7=CC=C(C=C7)C(NS(C8=CC(S(=O)(C(F)(F)F)=O)=C(C=C8)N[C@H](CCN9CCOCC9)CSC%10=CC=CC=C%10)(=O)=O)=O.OC(C(F)(F)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients. [Abstract]2025 Mar 19;26(6):2772. PMID: 40141414 -
Biochem Biophys Res Commun
Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. [Abstract]2022 Oct 1:623:120-126. PMID: 35921705 -
-
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yi Xu, et al. Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. Biochem Biophys Res Commun. 2022 Oct 1;623:120-126. [Content Brief]
[2]. Pratik Pal, et al. Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition. J Med Chem. 2021 Oct 14;64(19):14230-14246. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PZ703b TFA Related Classifications
HY-115718A Related Classifications
Powered by Bioz